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General Review 
• How well the report:
– Explains the current state of knowledge about 
the risk;
– Summarizes the critical areas of debate about 
the risk;
– Identifies the main gaps in knowledge or 
fundamental research about the risk; and
– Addresses possible interactions between the risk 
of unpredicted medication effects and other risks 
identified in NASA’s evidence reports
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General Review 
• Current report public August 2011
– Update to report in review cycle; publish date unknown
– Captures essence of the risk
• Assumptions are terrestrial practice = microgravity practice
– Report lists seven systems that could be impacted by 
the risk
– Other evidence report reviews that involve medication 
are compounded by the unknown aspects of this risk
• Bone, DCS, renal stone, reduced muscle mass (IM injection)
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General Review 
• Two major concerns highlighted
– Pharmacokinetics/Pharmacodynamics (PK/PD)
• The absence of evidence doesn’t mean there is no risk
– Extremely limited concrete information available
• The use of medications without data to support their 
actual activities is a risk to the crewmember and the 
mission
– Microgravity ‘patients’ are a specialized population due to 
the systemic changes that are known to occur
» additional changes/issues should be expected
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General Review 
• Two major concerns highlighted
– Stability of Medications
• Answers to the questions regarding the stability of the 
medications are not complete
– Do shelf-life rules apply?
– Need solid data to support extension for future missions
– Information would help drive contents of medical kits
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Clinical Pharmacy Perspective
• Question: Are there any operationally-relevant issues which 
have occurred over the years you worked for NASA?
• Question: Are there any issues you have raised which have 
NOT been addressed effectively?
– Evidence report and the information therein are relevant to 
operations and in my opinion have not been addressed 
effectively
– Stability of Medications
• Medication expiration date consistently questioned
– Resupply upmass, time, trash
– Reality of pharmacy operations
» Pharmacy regulations come into play
» Market changes
– Medical kit design and selection of medication
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Clinical Pharmacy Perspective
• Question: Are there any operationally-relevant issues which 
have occurred over the years you worked for NASA?
• Question: Are there any issues you have raised which have 
NOT been addressed effectively?
– Confounding elements – is the drug ‘bad’ or is there a PK/PD issue?
• ‘Bad’ could mean expired, altered or both to the point of ineffectiveness
– Clinical and operational issues blend 
• Changes to body systems
• Medications used to treat symptoms
• Medications used to handle occupational hazards
• Polypharmacy at play
• Environmental/engineering constraints 
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Clinical Pharmacy Perspective
• Question: Are there any operationally-relevant issues 
which have occurred over the years you worked for 
NASA?
• Question: Are there any issues you have raised which 
have NOT been addressed effectively?
– Documentation of medication usage information
• Processes evolving to get better information
• Expect gaps due to crewmember’s desire
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Clinical Pharmacy Perspective
• We don’t know the extent to which spaceflight 
alters pharmacodynamics 
– Actively discussed ‘to do’ or ‘not to do’ research
• Anecdotally there is no clinically significantly alteration
– What about the asymptomatic clinically significant alteration?
– Clinical Pharmacy: ‘to do’ review and research
• The issue needs to be studied
– New clinical issues have developed during the ISS missions
– Is medication use a factor in new clinical issues?  If so, what is 
the cause?
• Exploration missions
– Reasonable to expect additional concerns/issues
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Clinical Pharmacy Perspective
• Insights regarding drug stability (pre, during and 
post-flight)
– Pre-flight is the terrestrial model
• Pharmacy Ops works hard to keep tabs on appropriate storage until 
spaceflight
– Temperature data captured during shipment
– During flight
• Current medical kits are stored in their manufacturer’s packaging 
wherever possible 
• Repackaging is kept to a minimum
• Research report pending on 6 medications returned from spaceflight
– Post-flight
• Medications not returned routinely
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Clinical Pharmacy Perspective
• Insights regarding drug stability (pre, during and 
post-flight)
– Forward work
• Integrated team looking at long-term and exploration flight 
concerns
• Work being conducted through ExMC
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Clinical Pharmacy Perspective
• Have any mitigation strategies regarding drug 
stability of particular dosage forms been altered 
as a consequence of the work Dr. Putcha's lab 
has been involved in (and published in the last 
10 years?) Please provide specifics.
– Mitigation strategies to date have been to select 
medications that have not been shown to be altered
– Change in how most medications are packed (now 
using manufacturer’s packaging wherever possible)
– Ongoing research by the Pharmacology Lab
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Clinical Pharmacy Perspective
• Are you aware of any specific drug misadventures 
which occurred as a consequence of likely altered 
PK/PD of a medication during spaceflight? Please 
provide specifics.
– I am not aware of any specific drug misadventures that 
have occurred as a consequence of likely altered PK/PD
• A systematic review has not been done to date
• Processes are under development to use an integrated 
approach to medication use evaluation with a multi-
disciplinary team
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Clinical Pharmacy Perspective
• In your professional opinion, what should the 
research priorities be with regards to PK/PD and 
spaceflight?
– Start with a baseline
• Based on the clinical medication use evaluation, 
direction for PK/PD research is an expected outcome
– In-flight research is necessary
• One year mission
– Needs to happen while on station and continue 
through to the next generation of missions
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Clinical Pharmacy Perspective
• Evidence Report Review Summary
– Current report captures the knowledge gap that exists 
with respect to the risk of therapeutic failure due to 
ineffectiveness of medication
– Active research requests being made – hopefully 
translates to funding
– The use of medications will continue to occur as we 
transition into exploration missions
– Need to understand the impacts of the environment on 
medications and the interactions between pharmacologic 
therapy and the microgravity population to better inform 
clinical care
15
